Harvard Bioscience, Inc. HBIO
Set alert
At close · Nov 2
After hours · Nov 2, 4:00 PM ET
- YTD
- +28.36%
- 1 year
- +65.38%
- Open
- 9.00
- Prev close
- 8.90
- Mkt cap
- 39.15M
- Vol
- 28.61K
- Avg vol
- 19.28K
- EPS
- -2.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.60
- High
- 9.10
- Forward P/E
- 14.00
- Beta
- 1.31
- Short ratio
- 2.66
- Inst. own
- 75.99%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.30
- 200-d avg
- 3.04
- 1y target
- 6.25
5D chart
Signals (72)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 2, 2:05 PM | 11 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 12 hours ago |
| SMA: Bearish | Nov 2, 1:00 PM | 12 hours ago |
| RSI: Oversold | Nov 2, 1:00 PM | 12 hours ago |
| MACD: Sell Signal | Nov 2, 10:35 AM | 14 hours ago |
| SMA: Bearish | Nov 2, 10:25 AM | 14 hours ago |
| SMA: Bullish | Nov 2, 10:10 AM | 14 hours ago |
| RSI: Overbought | Nov 2, 10:10 AM | 14 hours ago |
| SMA: Bearish | Nov 2, 10:00 AM | 15 hours ago |
| RSI: Overbought | Oct 30, 3:40 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 3:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 2:30 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 2:30 PM | 3 days ago |
| RSI: Overbought | Oct 30, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:35 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 30, 10:45 AM | 3 days ago |
| RSI: Overbought | Oct 30, 9:40 AM | 3 days ago |
| SMA: Bullish | Oct 29, 3:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 29, 3:50 PM | 4 days ago |
Newest 20 of 72.
News
6 days ago globenewswire.com
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on…
3 weeks ago globenewswire.com
Harvard Bioscience Announces Creation of Scientific Advisory Board
HOLLISTON, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced the creation of its Scientific Advisory Board (SAB) to guide the Company's ongoing…
-
2 months ago benzinga.com
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.
2 months ago seekingalpha.com
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) Q2 2026 Earnings Call Transcript
-
2 months ago benzinga.com
Harvard Bioscience Sees FY2026 Sales $89.147M-$90.877M vs $88.600M Est.
Harvard Bioscience (NASDAQ:HBIO) sees FY2026 sales of $89.147 million-$90.877 million vs $88.600 million analyst estimate. Raises Full Year 2026 Revenue Guidance to 3%-5% Year Over Year Growth.
-
2 months ago benzinga.com
Harvard Bioscience Sees Q3 Sales $21.000M-$22.600M vs $21.850M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q3 sales of $21.000 million-$22.600 million vs $21.850 million analyst estimate.
-
2 months ago benzinga.com
Harvard Bioscience Q2 Adj. EPS $(0.14) Beats $(0.21) Estimate, Sales $22.727M Beat $21.450M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.21) by 33.33 percent. This is a 40 percent decrease over losses of…
3 months ago globenewswire.com
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET
HOLLISTON, Mass. , July 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended June 30, 2026, before the market opens on August…
-
5 months ago benzinga.com
Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026
On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company") appointed Michael A. Rossi to serve as the Company's Interim Chief Financial Officer and principal financial…
5 months ago seekingalpha.com
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
5 months ago benzinga.com
Harvard Bioscience Q1 2026 Earnings Call Transcript
Harvard Bioscience Q1 2026 Earnings Call Transcript
-
5 months ago benzinga.com
Harvard Bioscience Sees Q2 Sales $20.500M-$22.500M vs $21.900M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q2 sales of $20.500 million-$22.500 million vs $21.900 million analyst estimate.
-
5 months ago benzinga.com
Harvard Bioscience Q1 Adj. EPS $(0.33) Beats $(0.62) Estimate, Sales $20.755M Miss $21.200M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.62) by 46.77 percent. This is a 230 percent decrease over losses of…
5 months ago globenewswire.com
Harvard Bioscience Announces First Quarter 2026 Financial Results
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12,…
5 months ago globenewswire.com
Harvard Bioscience to Participate in Upcoming Investor Conferences
HOLLISTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced Chief Executive Officer, John Duke and Chief Financial Officer, Mark Frost's participation…
6 months ago globenewswire.com
Harvard Bioscience Schedules First Quarter 2026 Earnings Conference Call for May 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2026, before the market opens on May…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
6 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
-
7 months ago benzinga.com
Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $6
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $0.6 to $6.
7 months ago defenseworld.net
Harvard Bioscience Q4 Earnings Call Highlights
Harvard Bioscience (NASDAQ: HBIO) executives highlighted a year of "foundation building" and cost and balance sheet actions while outlining expectations for a return to growth in 2026 during the…
-
7 months ago benzinga.com
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $0.6
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $2 to $0.6.
7 months ago seekingalpha.com
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
-
7 months ago benzinga.com
Harvard Bioscience Sees Q1 Sales $20.000M-$22.000M vs $21.250M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q1 sales of $20.000 million-$22.000 million vs $21.250 million analyst estimate.
-
7 months ago benzinga.com
Harvard Bioscience Q4 Sales $23.735M Beat $23.100M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $23.735 million which beat the analyst consensus estimate of $23.100 million by 2.75 percent. This is a 3.34 percent decrease over sales…
7 months ago globenewswire.com
Harvard Bioscience Announces Fourth Quarter and Full-Year 2025 Financial Results
Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7% Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7% Interim CFO Mark Frost Appointed CFO on Permanent Basis Introduces Full…
-
7 months ago benzinga.com
Earnings Scheduled For March 12, 2026
Earnings Scheduled For March 12, 2026
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
8 months ago benzinga.com
Harvard Bioscience Board Approves 1-For-10 Reverse Stock Split, Effective March 13
Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc.…
8 months ago globenewswire.com
Harvard Bioscience Announces Reverse Stock Split
Harvard Bioscience's common stock is expected to begin trading on a post-split adjusted basis on March 16, 2026 HOLLISTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:…
8 months ago defenseworld.net
Harvard Bioscience (NASDAQ:HBIO) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened
Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of…
8 months ago globenewswire.com
Harvard Bioscience to Participate in KeyBanc's Virtual Healthcare Forum
HOLLISTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that John Duke, President and Chief Executive Officer, and Mark Frost, Interim Chief…
8 months ago globenewswire.com
Harvard Bioscience Schedules Fourth Quarter 2025 Earnings Conference Call for March 12, 2026 at 8:00 AM ET
HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on…
8 months ago defenseworld.net
Harvard Bioscience (NASDAQ:HBIO) Stock Crosses Below 200 Day Moving Average – Time to Sell?
Shares of Harvard Bioscience, Inc. (NASDAQ: HBIO - Get Free Report) crossed below its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $0.56 and traded as…
-
8 months ago benzinga.com
Harvard Bioscience Reports Q4 Preliminary Revenue Of $23.7M
Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), a global leader in life science research tools, today announced preliminary financial results for the fourth quarter…
8 months ago globenewswire.com
Harvard Bioscience Announces Preliminary Fourth Quarter Financial Results, Positive Outlook for 2026 & Outlines Long-Term Strategic Focus Areas
Reports preliminary fourth quarter revenue in line with guidance, gross margin at high end of guidance, and strong year over year adjusted EBITDA performance Expects year over year revenue growth and…
9 months ago benzinga.com
Harvard Bioscience Trims Footprint To Run Leaner, Faster, And Cheaper
Harvard Bioscience restructures production, closing MA plant, shifting output to US and abroad. Savings expected, costs until 2027.
9 months ago globenewswire.com
Harvard Bioscience Announces Strategic Consolidation of Manufacturing Operations to Improve Efficiency and Support Long-Term Growth
Streamlining production footprint and improving manufacturing efficiency through phased closure of Holliston, MA plant Initiative expected to deliver approximately $3 million in cost savings in 2027…
-
10 months ago benzinga.com
Harvard Bioscience Strikes Agreement With BroadOak Capital Partners To Offer $40M Credit Facility Of Three Term Loans
Harvard Bioscience, Inc. (Nasdaq: HBIO) (the "Company" or "Harvard Bioscience"), today announced it entered into an agreement with BroadOak Capital Partners (collectively, "BroadOak"), a…
10 months ago globenewswire.com
Harvard Bioscience Announces the Successful Completion of Debt Refinancing with Comprehensive Growth Financing Package
Completes Repayment of Existing Credit Agreement, Extends Debt Maturity, and Enhances Financial Flexibility BroadOak Partner Bill Snider to Join Board of Directors and Company to Form Advisory Board…
-
12 months ago benzinga.com
Harvard Bioscience Sees Q4 Sales $22.500M-$24.500M vs $23.100M Est
Harvard Bioscience (NASDAQ:HBIO) sees Q4 sales of $22.500 million-$24.500 million vs $23.100 million analyst estimate.
-
12 months ago benzinga.com
Harvard Bioscience Q3 Sales $20.591M Beat $20.000M Estimate
Harvard Bioscience (NASDAQ:HBIO) reported quarterly sales of $20.591 million which beat the analyst consensus estimate of $20.000 million by 2.96 percent. This is a 6.28 percent decrease over sales…
12 months ago benzinga.com
Earnings Scheduled For November 6, 2025
Earnings Scheduled For November 6, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
1 year ago benzinga.com
Benchmark Maintains Speculative Buy on Harvard Bioscience, Lowers Price Target to $2
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and lowers the price target from $3 to $2.